Pharma Aids Limited announcements
270 Dhaka Stock Exchange announcements for Pharma Aids Limited (PHARMAID) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2022 (23).
- Purchase and installation of a brand new oven
Refer to their earlier news disseminated by DSE on 07.10.2021 regarding decision to purchase 1 Annealing Electrical Oven, the company has further informed that the new oven had been purchased and its installation was completed on December 01, 2022. Total investment amount is Tk. 18,50,000.00.
- Resumption after record date
Trading of the shares of the Company will resume on 11.12.2022 after record date.
- National Credit Ratings Limited (NCR) has assigned the surveillance entity rating of the Company as \"A\" in the long te
National Credit Ratings Limited (NCR) has assigned the surveillance entity rating of the Company as \"A\" in the long term and \"ST-2\" in the short term along with a stable outlook based on audited financial statements of the Company as on June 30, 2022.
- Suspension for Record date
Trading of the shares of the Company will remain suspended on record date i.e., 08.12.2022.
- Update of Information
The Company has requested the Shareholders bearing BO ID to update their details of Bank Account No., e-mail address, change of address, mobile number, and 12-digit Tax Payers' identification number (e-TIN) through their respective brokerage houses/depository participants(DP).
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 06.12.2022 to 07.12.2022. Trading of the shares will remain suspended on record date i.e., 08.12.2022.
- The auditor of the Pharma Aids Limited has given the \"Qualified Opinion\" and \"Emphasis of Matter\" paragraphs in the
The auditor of the Pharma Aids Limited has given the \"Qualified Opinion\" and \"Emphasis of Matter\" paragraphs in the Auditor\'s Report for the year ended 30 June 2022. Basis for Qualified Opinion: I) The Company has debit balance with related party of Tk. 27,972,411 shown as other receivable in note no. 4.00 in these financial statement, which should be disclosed as related party transaction disclosure in note no. 36.00. (cont.1)
- (Continuation news of PHARMAID): But, no such disclosure has been made in this financial statements. Moreover, no intere
(Continuation news of PHARMAID): But, no such disclosure has been made in this financial statements. Moreover, no interest is charged/accrued during the year on related party debit balance. Emphasis of Matter: We draw users\' attention to Note no. 08.04 to the financial statements that discloses shareholding position of sponsors and directors at 24.22\% of paid up capital as on June 30, 2022 which falls short to the minimum require shareholding of 30\% of paid up capital as per BSEC Notification (cont.2)
The first part of this announcement is missing from the archive. - Qualified Opinion and Emphasis of Matter
(Continuation news of PHARMAID): No. BSEC/CMRRCD/2009-193/217/Admin/90 dated 21st May 2019. Our opinion is not modified in this matter. (end)
The first part of this announcement is missing from the archive. - (Continuation news of PHARMAID): changes in accounting estimates with respect to provision for gratuity, write off an un
(Continuation news of PHARMAID): changes in accounting estimates with respect to provision for gratuity, write off an unsettled VAT case, decrease in production resulting from power shortages, gas and fuel supply shortages, devaluation of BD Taka against US Dollar, increased price of production raw materials and inflation. NOCFPS has been decreased due to increase in payment to suppliers resulting from increased exchange rate and increase in tax payment. (end)
The first part of this announcement is missing from the archive. - Q1 Financials
(Q1 Un-audited): EPS was Tk. 1.99 for July-September 2022 as against Tk. 5.15 for July-September 2021; NOCFPS was Tk. 0.13 for July-September 2022 as against Tk. 3.37 for July-September 2021. NAV per share was Tk. 100.65 as on September 30, 2022 and Tk. 98.83 as on June 30, 2022. Reasons for significant deviation: EPS has been decreased due to application of deferred tax expense and deferred tax liability, provision for bad debt expenses, (cont.)
- The Board of Directors has recommended 50\% cash dividend for the year ended June 30, 2022. Date of AGM: 27.12.2022, Tim
The Board of Directors has recommended 50\% cash dividend for the year ended June 30, 2022. Date of AGM: 27.12.2022, Time: 11:30 AM, Venue: Digital Platform. Record date: 08.12.2022. The Company has reported EPS of Tk. 11.14, NAV per share of Tk. 98.83 and NOCFPS of Tk. 10.85 for the year ended June 30, 2022 as against Tk. 16.11, Tk. 93.26 and Tk. 10.07 respectively for the same period of the previous year. (cont.)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (10.11.2022) following its corporate declaration. However, as per the BSEC Order No. BSEC/CMRRCD/2001-07/39 dated July 28, 2022, the floor price shall be applicable accordingly.
- Dividend Declaration
(Continuation news of PHARMAID): Reasons for significant deviation in EPS: EPS significantly decreased mostly due to Deferred Tax Expense and Deferred Tax Liability, Provision for Bad Debt Expenses, changes in Accounting Estimates with respect to Provision for Gratuity and Write-off of an unsettled VAT Case that was shown as an asset in prior years. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2022.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 09, 2022 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2022.
- (Continuation news of PHARMAID): EPS increased due to increase in sales. NOCFPS increased due to increase in collection
(Continuation news of PHARMAID): EPS increased due to increase in sales. NOCFPS increased due to increase in collection from revenue and others. NAV increased due to increase in sales and increase in retained earnings. (end)
The first part of this announcement is missing from the archive. - Q3 Financials
(Q3 Un-audited): EPS was Tk. 4.63 for January-March 2022 as against Tk. 4.12 for January-March 2021; EPS was Tk. 15.31 for July 2021-March 2022 as against Tk. 12.17 for July 2020-March 2021. NOCFPS was Tk. 15.37 for July 2021-March 2022 as against Tk. 9.97 for July 2020-March 2021. NAV per share was Tk. 103.15 as on March 31, 2022 and Tk. 93.26 as on June 30, 2021. (cont.)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2022 at 2:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2022.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2021 to the respective shareholders.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 5.53 for October-December 2021 as against Tk. 4.03 for October-December 2020; EPS was Tk. 10.69 for July-December 2021 as against Tk. 8.05 for July-December 2020. NOCFPS was Tk. 14.56 for July-December 2021 as against Tk. 13.89 for July-December 2020. NAV per share was Tk. 98.66 as on December 31, 2021 and Tk. 93.26 as on June 30, 2021.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2022 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2021.
- Query Response
In response to a DSE query dated January 20, 2022, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike and increase in volume of shares.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.